Robinson Pharma Inc. (RPI), after more than one year of continuous research and development collaboration, is delighted to announce the introduction of its Unique IS-2™ Probiotic Softgel. RPI began a collaboration with B&D Nutritional Ingredients Inc., and its supplier, Unique Biotech USA and Unique Biotech Ltd. India, in the creation of an active, shelf-stable-guaranteed yield probiotic softgel that delivers a well-researched strain of beneficial bacteria. The Unique IS-2™ Bacillus coagulans strain has been the subject of numerous human clinical trials. The challenge and accomplishment was putting these organisms into an easy to swallow, shelf-stable soft gelatin dosage.
The Unique IS-2™ Probiotic Softgel in based on the Unique IS-2 Bacillus coagulans strain, a trademarked bacterium, which has demonstrated high resistance to extreme temperature and humidity. In addition to temperature stability, the strain is also resistant to gastric acids and the ability to survive transit through the gastrointestinal tract. The strain type has been the subject of published peer-reviewed journal articles investigating safety and relevance to specific health conditions.
“The specific challenges of creating a stable and active probiotic softgel is multifaceted and rigorous,” stated Fred Jamee, senior vice president and chief quality officer at Robinson Pharma Inc. “First one must identify a strain type that has the potential to survive the manufacturing process. More challenging is testing for the presence and viability of the probiotic after encapsulation. Recovery of the active probiotic from the lipid matrix of a softgel is not easy. Finally and more rigorous still, is creating a product that can withstand the challenges of time, in this case passing an accelerated stability study. Collaboration between the teams at Unique Biotech, B&D Nutritional Ingredients and Robinson Pharma Inc. resulted in a successful solution to these challenges. The analytical results of this project were confirmed by a reputable third-party laboratory using a published analytical method. Genus species and strain confirmation in finished product was confirmed through genome analysis utilizing DNA sequencing."
Upon the recent completion of this important work, B&D Nutritional Ingredients, the exclusive US distributor of Unique IS-2™, with full support from Unique Biotech, and Robinson Pharma Inc. signed an exclusive agreement for the production and sale of soft gelatin capsules containing this high value strain. Robinson Pharma has initiated marketing of this breakthrough product and already forecasts a robust market introduction later this year.